News >

FDA Grants Ribociclib Breakthrough Designation for HR+/HER2- Premenopausal Breast Cancer

Jason M. Broderick @jasoncology
Published: Wednesday, Jan 03, 2018

Samit Hirawat, executive vice president and head, Global Drug Development at Novartis Oncology

Samit Hirawat
The FDA has granted ribociclib (Kisqali) a breakthrough therapy designation for use in combination with tamoxifen or an aromatase inhibitor (AI) as frontline treatment for pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.

Ribociclib is currently approved by the FDA  for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone-receptor–positive, HER2-negative advanced breast cancer.
Tripathy D, Sohn J, Im SA, et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial. Presented at: the 2017 San Antonio Breast Cancer Symposium; Dec. 5-9, 2017. Abstract GS2-05.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast CancerDec 31, 20191.0
Medical Crossfire®: A Critical Assessment of Current and Emerging Data Sets to Move Treatment of Triple-Negative Breast Cancer ForwardJan 31, 20201.0
Publication Bottom Border
Border Publication
x